EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 326 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR What Is Pancreatic Enzyme Replacement Therapy in Cancer Care? June 22, 2021 From smouldering ash to a gleaming temple for cancer research: The... April 26, 2023 17 Old Fashioned Ways to Get Rid of Ants in Your... March 27, 2019 Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma July 1, 2020 Load more HOT NEWS Cancer Survivor And His Organ Donor Run NYC Marathon Together To... Lack of Evidence for the Use of Telemedicine in the Prevention... Experimental mRNA Vaccine Hints at Potential Against Glioblastoma New targeted treatments raise the bar in immunotherapy-resistant melanoma
